Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T19:48:07.836Z.
Calculation as of: 2026-10-06T19:48:07.836Z.
Quote observation: 2026-10-06T19:45:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: caaf80bca5ccea9457018b34cf7693b2821ca050e30c360cba938cf84e67b366
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
LB Pharmaceuticals Inc Common Stock
Market Cap
$978.73M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$981.10M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$976.80M
Operating Cash Flow Yield
1.40%
TTM Avg
0.99%
3Y Avg
0.99%
5Y Avg
0.99%
Market Cap
$969.12M
Operating Cash Flow Yield
19.36%
TTM Avg
14.96%
3Y Avg
15.37%
5Y Avg
11.65%
Market Cap
$992.10M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$992.39M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.00B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$954.07M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LB Pharmaceuticals Inc Common Stock (LBRX) | $978.73M | N/A | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $981.10M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $976.80M | 1.40% | 0.99% | 0.99% | 0.99% |
| Pacira BioSciences, Inc. (PCRX)vs › | $969.12M | 19.36% | 14.96% | 15.37% | 11.65% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $992.10M | N/A | N/A | N/A | N/A |
| Vor Biopharma Inc. (VOR)vs › | $992.39M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.00B | N/A | N/A | N/A | N/A |
| Savara Inc. (SVRA)vs › | $951.89M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $954.07M | N/A | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.01B | N/A | 1.54% | 13.01% | 70.14% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
